human growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Nucleotides === Containing both amines or imines and phosphoric acid groups, the nucleotides such as AMP, ADP, and ATP exist significantly as zwitterions, although the positive and negative charges are not necessarily balanced.
== Documentaries == The fires were the subject of a 1992 documentary film, Fires of Kuwait, which was nominated for an Academy Award. The film includes footage of the Hungarian team using their jet turbine extinguisher. Lessons of Darkness is a 1992 film by director Werner Herzog that explores the ravaged oil fields of post-Gulf War Kuwait. Bechtel Corporation produced a short documentary titled Kuwait: Bringing Back the Sun that summarizes and focuses upon the fire fighting efforts, which were dubbed the Al-Awda (Arabic for "The Return") project. Peter V. Hobbs also narrated a short amateur documentary titled Kuwait Oil Fires that followed the University of Washington's Cloud and Aerosol Research Group as they flew through, around, and above the smoke clouds and took samples, measurements, and videos of them in their Convair C-131 aerial laboratory.
=== csARDs === Conventional synthetic antirheumatic drugs (csARDs) are a class of disease-modifying medications. Unlike biologics or targeted synthetic drugs, which act on specific pathways in the immune system, csARDs have a broader effect on the immune system and are often considered traditional or conventional treatments. The most common drugs in this class are methotrexate and sulfasalazine. These medications are only used when others fail, or when certain specific conditions are met, and are often discontinued if a patient's symptoms become manageable with just a TNFi or other medication. Conventional DMARDs such as leflunomide are also considered to be part of this class. Concerns exist about a possible lack of efficacy of some drugs in this class.
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from The State of Food Security and Nutrition in the World 2024, FAO, IFAD, UNICEF, WFP and WHO, FAO. This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2026, Food and Agriculture Organization of the United Nations.
Sources: en.wikipedia.org
=== Humanitarian concerns === Critics have raised humanitarian concerns about the impact of U.S. sanctions on civilian populations. Daniel T. Griswold, writing from a conservative Christian perspective, argues that sanctions limit a sanctioned country's people from exercising political liberties and market freedom. In 1997, the American Association for World Health stated the US embargo against Cuba contributed to malnutrition, poor water access, and lack of access to medicine and other medical supplies. The impact of sanctions on mortality has been the subject of several studies. Economist Helen Yaffe estimates U.S. sanctions on Venezuela caused the deaths of 100,000 people between 2014 and 2020 due to difficulty importing medicine and health care equipment. A study by Mark Weisbrot and Jeffrey Sachs estimated sanctions contributed to approximately 40,000 excess deaths in Venezuela between 2017 and 2018, though critics argued the impact of sanctions could not be adequately separated from pre-existing negative trends. Comprehensive sanctions on Iraq by the United Nations Security Council during the 1990s were linked to widespread malnutrition, shortages of medicine, and deterioration of water and electricity infrastructure. A 1999 UNICEF study estimated between 400,000 and 500,000 excess deaths among children under 5 since 1991; however, surveys conducted after 2003 found no evidence of a large sustained rise in under-5 mortality beginning in 1991.
Wound bed preparation is an accepted strategy that facilitates wound management interventions. Management of wound exudate, bioburden and debridement are all associated with effective wound cleansing and are thus integral components of effectual wound bed preparation. Choice of cleansing solution should consider not only the piecemeal wound requirements but also the patient and be reinforced by a sound knowledge/experience base. This knowledge should include insight into bacterial phenotype 'behavior' and the most appropriate methods of management. Current findings indicate that PHMB in conjunction with a surfactant (betaine) is superior to Ringer's solution and saline when used as wound cleansers and also appears to demonstrate efficacy when used in wounds where biofilms are suspected or present.
=== Eggsquis === Eggsquis is a midscale chain of restaurants in Quebec and Ontario. As of 2018, there are 39 outlets, which are primarily in Quebec. It specializes in egg dishes, from bacon and eggs to omelettes. The first Eggsquis restaurant was opened by Elias Stergiou in Sherbrooke, in 1995. In 2010, the owners of the restaurant chain Chez Cora took Eggsquis to court, claiming that some of the dishes at its Mascouche location had been copied from Cora's, including the names of the dishes.
Belize is on the Caribbean coast of northern Central America. It shares a border on the north with the Mexican state of Quintana Roo, on the west with the Guatemalan department of Petén, and on the south with the Guatemalan department of Izabal. To the east in the Caribbean Sea, the second-longest barrier reef in the world flanks much of the 386 kilometres (240 mi) of predominantly marshy coastline. The area of the country totals 22,960 square kilometres (8,865 sq mi), an area slightly larger than El Salvador, Israel, New Jersey, or Wales. The many lagoons along the coasts and in the northern interior reduces the actual land area to 21,400 square kilometres (8,263 sq mi). It is the only Central American country with no Pacific coastline. Belize is shaped roughly like a rhombus that extends about 280 kilometres (174 mi) north-south and about 100 kilometres (62 mi) east-west, with a total land boundary length of 516 kilometres (321 mi). The undulating courses of two rivers, the Hondo and the Sarstoon River, delineate much of the country's northern and southern boundaries. The western border follows no natural features and runs north–south through lowland forest and highland plateau. The north of Belize consists mostly of flat, swampy coastal plains, in places heavily forested. The flora is highly diverse considering the small geographical area. The south contains the low mountain range of the Maya Mountains. The highest point in Belize is Doyle's Delight at 1,124 m (3,688 ft).
Although previous studies proposed that Komodo dragon saliva contains a variety of highly septic bacteria that would help to bring down prey, research in 2013 suggested that the bacteria in the mouths of Komodo dragons are ordinary and similar to those found in other carnivores. Komodo dragons have good mouth hygiene. To quote Bryan Fry: "After they are done feeding, they will spend 10 to 15 minutes lip-licking and rubbing their head in the leaves to clean their mouth ... Unlike people have been led to believe, they do not have chunks of rotting flesh from their meals on their teeth, cultivating bacteria." They do have a slashing bite, which normally includes a dose of their neurotoxic venom and anticoagulant saliva. Komodo dragons do not wait for prey to die and track it at a distance, as vipers do; observations of them hunting deer, boar and in some cases buffalo reveal that they kill prey in less than half an hour during successful hunts, and usually in a matter of a few minutes, similar to large mammalian carnivores. The observation of prey dying of sepsis is instead likely based on misinterpretations of failed predation attempts caused by the natural instinct of water buffalo, which are not native to the islands where the Komodo dragon lives, to run into water after escaping an attack. The warm, faeces-filled water would then cause the infections. The study used samples from 16 captive dragons (10 adults and six neonates) from three US zoos.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.